Jonathan Lindner elected president of the American Society of Echocardiography

The 17,000-member American Society of Echocardiography (ASE) named Jonathan R. Lindner, MD president of the organization on June 27 during its 29th annual scientific sessions in Nashville, Tennessee.

Lindner is currently director of cardiovascular imaging and professor of medicine at Oregon Health and Science University. He has served as ASE’s vice president and president-elect before being selected for a one-year term as president of the organization.

“I am honored and look forward to serving as ASE's 30th president,” Lindner said in a statement. “ASE is committed to improving healthcare not only in North America but worldwide through science, innovation, technology, and education. I plan on leveraging my background as a translational scientist to make sure our society continues to shape the evolution of cardiovascular ultrasound.”

In addition to electing Lindner, ASE also named the following new board of director members to two-year terms: Jayashri Aragam, MD, West Roxbury VA Hospital, Massachusetts; G. Burkhard Mackensen, MD, University of Washington Medical Center, Seattle; Michael Main, MD, Saint Luke's Mid America Heart Institute, Kansas City, Missouri; and Elaine Shea, Alta Bates Summit Medical Center, Oakland, California, Sonography Council Steering Committee Chair.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.